PRLD - Prelude Therapeutics Inc

QQQ $ 608.45 $ 0.46 (0.08 %)

DIA $ 471.65 $ -2.94 (-0.62 %)

SPY $ 671.62 $ -0.11 (-0.02 %)

TLT $ 88.93 $ -0.51 (-0.57 %)

GLD $ 375.82 $ -6.91 (-1.8 %)

Previous Close

$ 1.52

Open

$ 1.46

Bid

$ 1.48 x 200

Ask

$ 1.50 x 100

Day's Range

$ 1.43 - $ 1.53

52 Week Range

$ 0.61 - $ 4.22

Volume

572,420

Average Volume

Market Cap

95.56M

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-12-2025	09-30-2025	10-Q
2	08-14-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	03-10-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-12-2024	06-30-2024	10-Q
7	05-07-2024	03-31-2024	10-Q
8	02-15-2024	12-31-2023	10-K
9	11-01-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	05-08-2023	03-31-2023	10-Q
12	03-15-2023	12-31-2022	10-K
13	11-14-2022	09-30-2022	10-Q
14	08-09-2022	06-30-2022	10-Q
15	05-10-2022	03-31-2022	10-Q
16	03-17-2022	12-31-2021	10-K
17	11-12-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-11-2021	03-31-2021	10-Q
20	03-16-2021	12-31-2020	10-K
21	11-10-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
11/13/2025 21:06:42

Prelude Therapeutics Q3 EPS $(0.26) Beats ...
11/12/2025 12:06:45

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of ...

12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 17:06:03

dow-dips-over-400-points-pfizer-earnings-top-estimates

Dow Dips Over 400 Points; Pfizer Earnings ...
11/04/2025 14:53:19

Market-Moving News for November 4th
11/04/2025 12:24:43

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patie...

Trading Halt: Halt status updated at 7:15:...
11/04/2025 12:15:07

Prelude Therapeutics Signs Agreement For I...
11/04/2025 12:07:54

Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive opti...

12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 12:05:48

Trading Halt: Halted at 6:55:00 a.m. ET - ...
11/04/2025 11:55:04

12 Health Care Stocks Moving In Monday's A...
11/03/2025 21:12:06

Prelude Therapeutics Granted U.S. Patent #...
10/21/2025 20:00:30

https://ppubs.uspto.gov/api/pdf/downloadPdf/12448389?requestToken=eyJzdWIiOiJlZWQ3ZTE2MS1kZjI1LTQyNTktODVjNy02NmE4NGMzYWM1ZDciL...

HC Wainwright & Co. Reiterates Buy on Prel...
09/23/2025 11:08:35

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

JMP Securities Maintains Market Outperform...
08/18/2025 14:37:02

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

Prelude Therapeutics Q2 EPS $(0.41) Beats ...
08/14/2025 11:18:51

12 Health Care Stocks Moving In Tuesday's ...
05/27/2025 21:06:12

Prelude Therapeutics Q1 EPS $(0.42) Beats ...
05/06/2025 20:36:35

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

HC Wainwright & Co. Reiterates Buy on Prel...
05/05/2025 10:44:26

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

JMP Securities Reiterates Market Outperfor...
04/29/2025 16:36:21

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

HC Wainwright & Co. Reiterates Buy on Prel...
04/08/2025 11:24:22

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...